|
1
|
Stevceva L, Pavli P, Husband AJ and Doe
WF: The inflammatory infiltrate in the acute stage of the dextran
sulphate sodium induced colitis: B cell response differs depending
on the percentage of DSS used to induce it. BMC Clin Pathol.
1:32001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bennink RJ, Hamann J, de Bruin K, ten Kate
FJ, van Deventer SJ and te Velde AA: Dedicated pinhole SPECT of
intestinal neutrophil recruitment in a mouse model of dextran
sulfate sodium-induced colitis. J Nucl Med. 46:526–531.
2005.PubMed/NCBI
|
|
3
|
Hyun JG, Lee G, Brown JB, et al:
Anti-interferon-inducible chemokine, CXCL10, reduces colitis by
impairing T helper-1 induction and recruitment in mice. Inflamm
Bowel Dis. 11:799–805. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rivera-Nieves J, Ho J, Bamias G, et al:
Antibody blockade of CCL25/CCR9 ameliorates early but not late
chronic murine ileitis. Gastroenterology. 131:1518–1529. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Farooq SM, Stillie R, Svensson M, Svanborg
C, Strieter RM and Stadnyk AW: Therapeutic effect of blocking CXCR2
on neutrophil recruitment and dextran sodium sulfate-induced
colitis. J Pharmacol Exp Ther. 329:123–129. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
MacDermott RP: Alterations of the mucosal
immune system in inflammatory bowel disease. J Gastroenterol.
31:907–916. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee HJ, Choi SC, Lee MH, et al: Increased
expression of MIP-3alpha/CCL20 in peripheral blood mononuclear
cells from patients with ulcerative colitis and its down-regulation
by sulfasalazine and glucocorticoid treatment. Inflamm Bowel Dis.
11:1070–1079. 2005. View Article : Google Scholar
|
|
8
|
ten Hove T, Drillenburg P, Wijnholds J, Te
Velde AA and van Deventer SJ: Differential susceptibility of
multidrug resistance protein-1 deficient mice to DSS and
TNBS-induced colitis. Dig Dis Sci. 47:2056–2063. 2002.PubMed/NCBI
|
|
9
|
te Velde AA, de Kort F, Sterrenburg E, et
al: Comparative analysis of colonic gene expression of three
experimental colitis models mimicking inflammatory bowel disease.
Inflamm Bowel Dis. 13:325–330. 2007.PubMed/NCBI
|
|
10
|
Murano M, Maemura K, Hirata I, et al:
Therapeutic effect of intracolonically administered nuclear factor
kappa B (p65) antisense oligonucleotide on mouse dextran sulphate
sodium (DSS)-induced colitis. Clin Exp Immunol. 120:51–58. 2000.
View Article : Google Scholar
|
|
11
|
Boirivant M, Fuss IJ, Ferroni L, De
Pascale M and Strober W: Oral administration of recombinant cholera
toxin subunit B inhibits IL-12-mediated murine experimental
(trinitrobenzene sulfonic acid) colitis. J Immunol. 166:3522–3532.
2001. View Article : Google Scholar
|
|
12
|
Koga H, Sakisaka S, Ohishi M, et al:
Expression of cyclooxygenase-2 in human hepatocellular carcinoma:
relevance to tumor dedifferentiation. Hepatology. 29:688–696. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Banks C, Bateman A, Payne R, Johnson P and
Sheron N: Chemokine expression in IBD. Mucosal chemokine expression
is unselectively increased in both ulcerative colitis and Crohn’s
disease. J Pathol. 199:28–35. 2003.PubMed/NCBI
|
|
14
|
Watanabe S, Yamakawa M, Hiroaki T, Kawata
S and Kimura O: Correlation of dendritic cell infiltration with
active crypt inflammation in ulcerative colitis. Clin Immunol.
122:288–297. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Uguccioni M, Gionchetti P, Robbiani DF, et
al: Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in
ulcerative colitis. Am J Pathol. 155:331–336. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
MacDermott RP, Sanderson IR and Reinecker
HC: The central role of chemokines (chemotactic cytokines) in the
immunopathogenesis of ulcerative colitis and Crohn’s disease.
Inflamm Bowel Dis. 4:54–67. 1998.PubMed/NCBI
|
|
17
|
Buanne P, Di Carlo E, Caputi L, et al:
Crucial pathophysiological role of CXCR2 in experimental ulcerative
colitis in mice. J Leukoc Biol. 82:1239–1246. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zimmerman NP, Vongsa RA, Wendt MK and
Dwinell MB: Chemokines and chemokine receptors in mucosal
homeostasis at the intestinal epithelial barrier in inflammatory
bowel disease. Inflamm Bowel Dis. 14:1000–1011. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sartor RB: Cytokines in intestinal
inflammation: pathophysiological and clinical considerations.
Gastroenterology. 106:533–539. 1994.PubMed/NCBI
|
|
20
|
Ashwood P, Harvey R, Verjee T,
Wolstencroft R, Thompson RP and Powell JJ: Functional interactions
between mucosal IL-1, IL-ra and TGF-beta 1 in ulcerative colitis.
Inflamm Res. 53:53–59. 2004.PubMed/NCBI
|
|
21
|
Izadpanah A, Dwinell MB, Eckmann L, Varki
NM and Kagnoff MF: Regulated MIP-3alpha/CCL20 production by human
intestinal epithelium: mechanism for modulating mucosal immunity.
Am J Physiol Gastrointest Liver Physiol. 280:G710–G719.
2001.PubMed/NCBI
|
|
22
|
Jin Y, Fuller L, Ciancio G, et al: Antigen
presentation and immune regulatory capacity of immature and
mature-enriched antigen presenting (dendritic) cells derived from
human bone marrow. Hum Immunol. 65:93–103. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kaser A, Ludwiczek O, Holzmann S, et al:
Increased expression of CCL20 in human inflammatory bowel disease.
J Clin Immunol. 24:74–85. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
He C, Zhang SL, Hu CJ, Tong DW and Li YZ:
Higher levels of CCL20 expression on peripheral blood mononuclear
cells of chinese patients with inflammatory bowel disease. Immunol
Invest. 39:16–26. 2010. View Article : Google Scholar : PubMed/NCBI
|
